. 2021 Nov 11;53(1):2072–2089. doi: 10.1080/07853890.2020.1841281
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 6.
Summary of the main studies with SGLT2 inhibitors and renal outcomes.